ArticleAnnals of clinical and translational neurology2018
Cerebral autoinflammatory disease treated with anakinra.
Article in Annals of clinical and translational neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient Management.Advances in therapy · 2026Review
- The cell-mediated adaptive immune response to herpes simplex virus type 1 encephalitis: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.Journal of neurology · 2024Article
- Improvement of cognitive function in wild-type and Alzheimer´s disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells.Frontiers in immunology · 2023Article
- A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome.Frontiers in neurology · 2023Review
- Treatment Options in Refractory Autoimmune Encephalitis.CNS drugs · 2022Review
- Anakinra treatment for refractory cerebral autoinflammatory responses.Annals of clinical and translational neurology · 2022Article
- A 9-Year-Old Patient with Recurrent Fever, Urticarial Rash and Demyelinating Brain Lesions: NLRP3-Autoinflammatory Disease in Ecuador.Open access rheumatology : research and reviews · 2022Article
- Super refractory status in a case of Febrile Infection-Related Epilepsy Syndrome due to hemophagocytic lymphocytic histiocytosis.Epilepsia open · 2021Review
- Therapeutic Strategies for Targeting IL-1 in Cancer.Cancers · 2021Review
- Clinical Approach to Autoimmune Epilepsy.Journal of clinical neurology (Seoul, Korea) · 2020Review
- Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.Life sciences · 2020Review
- Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in autoimmune encephalitis has been growing since the discovery of various autoimmune antibodies, such as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.